Filing Overview
Company: Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a Delaware corporation and emerging growth company.
Report date: September 24, 2026. This Form 8-K reports Regulation FD disclosure under Item 7.01 and furnishes a related press release as Exhibit 99.1.
Business Context
The company announced positive one-year data from the registrational KYSA-8 trial of mivocabtagene autoleucel (miv-cel, also called KYV-101) in patients with stiff person syndrome, as well as positive longer-term follow-up data from the Phase 2 portion of the registrational KYSA-6 trial in patients with generalized myasthenia gravis.
Kyverna stated that it would host a conference call at 8:00 a.m. Eastern Time on September 24, 2026, to review the results.
Financial and Operating Metrics
This filing does not provide revenue, profit or loss, cash flow, operating margin, debt, liquidity, cash balance, or other financial metrics.
The filing text provided does not include the detailed clinical data, statistical results, safety findings, or financial information contained in the furnished press release.
Material Changes and Unusual Items
- The reported development is the release of clinical trial data for miv-cel in stiff person syndrome and generalized myasthenia gravis.
- No material changes to financial condition, capital structure, debt, liquidity, or operations are disclosed in the provided filing text.
- Item 7.01 information, including Exhibit 99.1, is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except where expressly stated.
Guidance, Outlook, and Risks
No financial guidance or explicit forward-looking outlook is provided in the filing text. Investors should review the furnished press release and related conference-call materials for the underlying trial results, regulatory implications, development timelines, safety profile, and associated risks.
Important Facts to Verify
- Verify the full one-year KYSA-8 efficacy and safety results in stiff person syndrome.
- Verify the longer-term KYSA-6 follow-up results in generalized myasthenia gravis.
- Assess patient numbers, response durability, endpoints, statistical significance, and adverse events.
- Review any regulatory, clinical-development, manufacturing, financing, or cash-runway implications described in Exhibit 99.1 or the conference call.
- Confirm that the press release and clinical claims are furnished under Item 7.01 and are subject to the filing’s stated incorporation and liability limitations.